Oleg Gladkov
Chelyabinsk State University(RU)
Publications by Year
Research Areas
Lung Cancer Treatments and Mutations, Colorectal Cancer Treatments and Studies, Cancer Treatment and Pharmacology, Renal cell carcinoma treatment, Gastric Cancer Management and Outcomes
Most-Cited Works
- → Pazopanib in Locally Advanced or Metastatic Renal Cell Carcinoma: Results of a Randomized Phase III Trial(2010)2,472 cited
- → Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial(2021)783 cited
- → HER2 screening data from ToGA: targeting HER2 in gastric and gastroesophageal junction cancer(2014)592 cited
- → Tecemotide (L-BLP25) versus placebo after chemoradiotherapy for stage III non-small-cell lung cancer (START): a randomised, double-blind, phase 3 trial(2013)522 cited
- → Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial(2016)493 cited
- → A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: Final overall survival results and safety update(2013)443 cited
- → Phase Ib Study of PEGylated Recombinant Human Hyaluronidase and Gemcitabine in Patients with Advanced Pancreatic Cancer(2016)320 cited
- → Efficacy and safety of lipegfilgrastim versus pegfilgrastim: a randomized, multicenter, active-control phase 3 trial in patients with breast cancer receiving doxorubicin/docetaxel chemotherapy(2013)90 cited
- → Sorafenib in Combination with Oxaliplatin, Leucovorin, and Fluorouracil (Modified FOLFOX6) as First-line Treatment of Metastatic Colorectal Cancer: The RESPECT Trial(2013)90 cited
- → A randomized phase II study of lapatinib + pazopanib versus lapatinib in patients with HER2+ inflammatory breast cancer(2012)79 cited